Results from a small scale nonrandomized phase II human trial failed to show clinical efficacy in patients with metastatic and/or recurrent Ewing sarcoma treated with only olaparib (Choy et al., 2014), but other trials are underway to explore the efficacy of PARP inhibition in combination with chemotherapy. Here, PARP1 is linked to Ewing sarcoma.